

Stephane Chauvie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9285611/publications.pdf>

Version: 2024-02-01

98
papers

27,260
citations

304602

22
h-index

106281

65
g-index

99
all docs

99
docs citations

99
times ranked

20926
citing authors

#	ARTICLE	IF	CITATIONS
1	Geant4—a simulation toolkit. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2003, 506, 250-303.	0.7	17,893
2	Geant4 developments and applications. IEEE Transactions on Nuclear Science, 2006, 53, 270-278.	1.2	4,869
3	Recent developments in Geant4. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2016, 835, 186-225.	0.7	2,327
4	International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers. Journal of Nuclear Medicine, 2013, 54, 683-690.	2.8	267
5	The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica, 2014, 99, 1107-1113.	1.7	225
6	Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. Journal of Clinical Oncology, 2018, 36, 454-462.	0.8	169
7	Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. British Journal of Haematology, 2011, 152, 551-560.	1.2	127
8	¹⁸ F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia, 2016, 30, 417-422.	3.3	120
9	Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian) Tj ETQq1 1 0.784314 rgBT /Over 712-719.	3.3	95
10	Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET Use). European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 414-421.	3.3	92
11	Development of standardized image interpretation for ⁶⁸ Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1622-1635.	3.3	91
12	Recent Improvements in Geant4 Electromagnetic Physics Models and Interfaces. Progress in Nuclear Science and Technology, 2011, 2, 898-903.	0.3	87
13	Geant4 Physics Processes for Microdosimetry Simulation: Design Foundation and Implementation of the First Set of Models. IEEE Transactions on Nuclear Science, 2007, 54, 2619-2628.	1.2	86
14	Standardization of ¹⁸ F-FDG PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 116-125.	0.8	85
15	Metabolic Tumor Volume Metrics in Lymphoma. Seminars in Nuclear Medicine, 2018, 48, 50-66.	2.5	75
16	Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. Leukemia, 2015, 29, 1360-1365.	3.3	57
17	Reversible impairment of coronary flow reserve in takotsubo cardiomyopathy: A myocardial PET study. Journal of Nuclear Cardiology, 2008, 15, 811-817.	1.4	52
18	The role of PET/CT in the modern treatment of Hodgkin lymphoma. Cancer Treatment Reviews, 2019, 77, 44-56.	3.4	51

#	ARTICLE	IF	CITATIONS
19	Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3905-3913.	0.8	36
20	Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1005-1015.	3.3	35
21	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 729-739.	0.8	34
22	Reversible inverse mismatch in transient left ventricular apical ballooning: Perfusion/metabolism positron emission tomography imaging. <i>Journal of Nuclear Cardiology</i> , 2006, 13, 587-590.	1.4	22
23	WIDEN: A tool for medical image management in multicenter clinical trials. <i>Clinical Trials</i> , 2014, 11, 355-361.	0.7	22
24	Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study. <i>Hematological Oncology</i> , 2017, 35, 548-553.	0.8	22
25	The 68 Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian) Tj ETQq1 1 0,784314 rgBT /Ov	0,4	20
26	Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials. <i>Blood</i> , 2018, 132, 257-257.	0.6	20
27	Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1463-1464.	3.3	19
28	RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI.. <i>Hematological Oncology</i> , 2019, 37, 153-154.	0.8	19
29	Artificial intelligence and radiomics enhance the positive predictive value of digital chest tomosynthesis for lung cancer detection within SOS clinical trial. <i>European Radiology</i> , 2020, 30, 4134-4140.	2.3	17
30	The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients: the Polish Lymphoma Research Group (PLRG) Observational Study. <i>Annals of Oncology</i> , 2017, 28, 3051-3057.	0.6	16
31	PET-Derived Quantitative Metrics for Response and Prognosis in Lymphoma. <i>PET Clinics</i> , 2019, 14, 317-329.	1.5	16
32	Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis. <i>Hematological Oncology</i> , 2022, 40, 12-22.	0.8	13
33	Brentuximab vedotin followed by ABVD +/~ radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. <i>Haematologica</i> , 2016, 101, e139-e141.	1.7	12
34	Feasibility of Intensity-Modulated Radiation Therapy in the Treatment of Advanced Cervical Chordoma. <i>Tumori</i> , 2003, 89, 298-304.	0.6	11
35	The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-adapted HD0607 trial. <i>Cancer Medicine</i> , 2020, 9, 8735-8746.	1.3	10
36	Myocardial scar and insulin resistance predict cardiovascular events in severe ischaemic myocardial dysfunction: a perfusion+metabolism positron emission tomography study. <i>Nuclear Medicine Communications</i> , 2008, 29, 448-454.	0.5	9

#	ARTICLE	IF	CITATIONS
37	A powerful simulation tool for medical physics applications: Geant4. Nuclear Physics, Section B, Proceedings Supplements, 2003, 125, 80-84.	0.5	8
38	The Strategies to Homogenize PET/CT Metrics: The Case of Onco-Haematological Clinical Trials. Biomedicines, 2016, 4, 26.	1.4	8
39	Comparison of digital tomosynthesis and computed tomography for lung nodule detection in SOS screening program. Radiologia Medica, 2017, 122, 568-574.	4.7	8
40	Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial. Blood, 2012, 120, 550-550.	0.6	8
41	Geant4 Model for the Stopping Power of Low Energy Negatively Charged Hadrons. IEEE Transactions on Nuclear Science, 2007, 54, 578-584.	1.2	6
42	¹⁸ Fluorine-fluorodeoxyglucose positron emission tomography/computed tomography total glycolytic volume in thymic epithelial neoplasms evaluation: a reproducible image biomarker. General Thoracic and Cardiovascular Surgery, 2014, 62, 228-233.	0.4	6
43	A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYA. EJHaem, 2022, 3, 406-414.	0.4	6
44	Validation of Geant4 Bremsstrahlung models: first results. , 2006, , .		5
45	Reversible impairment of coronary flow reserve in takotsubo cardiomyopathy: A myocardial PET study. Journal of Nuclear Cardiology, 2008, 15, 811-817.	1.4	5
46	PET-derived metabolic volume metrics in lymphoma. Clinical and Translational Imaging, 2015, 3, 331-341.	1.1	5
47	Automatic liver detection and standardised uptake value evaluation in whole-body Positron Emission Tomography/Computed Tomography scans. Computer Methods and Programs in Biomedicine, 2018, 156, 47-52.	2.6	5
48	Monitoring response in lymphomas: qualitative, quantitative, or what else?. Leukemia and Lymphoma, 2019, 60, 302-308.	0.6	5
49	The Prognostic Role of Interim PET after First Chemotherapy Cycle and PET Sequential Evaluation of Response to ABVD in Hodgkin Lymphoma Patients - the Polish Lymphoma Research Group (PLRG) Observational Study. Blood, 2015, 126, 3943-3943.	0.6	5
50	A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report.. Journal of Clinical Oncology, 2014, 32, 8507-8507.	0.8	5
51	Dual-point FDG-PET/CT for treatment response assessment in Hodgkin lymphoma, when an FDG-avid lesion persists after treatment. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 176-184.	1.0	5
52	Monte Carlo dose calculation algorithm on a distributed system. Nuclear Physics, Section B, Proceedings Supplements, 2003, 125, 159-163.	0.5	3
53	Monte Carlo Simulation of Electromagnetic Interactions of Radiation with Liquid Water in the Framework of the Geant4-DNA Project. , 2006, , .		3
54	CONSOLIDATION RADIOTHERAPY COULD BE OMITTED IN ADVANCED HODGKIN LYMPHOMA WITH LARGE NODAL MASS IN COMPLETE METABOLIC RESPONSE AFTER ABVD. FINAL ANALYSIS OF THE RANDOMIZED HD0607 TRIAL. Hematological Oncology, 2019, 37, 147-148.	0.8	3

#	ARTICLE	IF	CITATIONS
55	The impact of time-of-flight, resolution recovery, and noise modelling in reconstruction algorithms in non-solid-state detectors PET/CT scanners: a multi-centric comparison of activity recovery in a 68Ge phantom. <i>Physica Medica</i> , 2020, 75, 85-91.	0.4	3
56	Brentuximab Vedotin Followed By ABVD in Patients with Previously Untreated Hodgkin Lymphoma. a Pilot Phase II Study. <i>Blood</i> , 2014, 124, 3088-3088.	0.6	3
57	Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose / Positron Emission Tomography in advanced Hodgkin lymphoma. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, , .	0.4	3
58	Lesion Dissemination in Baseline PET/CT (D-MAX) and IPS Score Predict ABVD Treatment Outcome in PET-2 Negative Advanced-Stage Hodgkin Lymphoma Patients Enrolled in the Prospective GITIL/FIL HD0607 Trial. <i>Blood</i> , 2021, 138, 2443-2443.	0.6	3
59	Radiomics in Malignant Lymphomas. , 0, , 71-82.		3
60	Geant4 model for the stopping power of low energy negatively charged hadrons. , 2006, , .		2
61	Models of biological effects of radiation in the Geant4 Toolkit. , 2006, , .		2
62	Evaluation of phase effects in Geant4 microdosimetry models for particle interactions in water. , 2007, , .		2
63	Correlation between delayed-enhancement magnetic resonance and nitrate myocardial Tc-99m tetrofosmin scintigraphy in myocardial infarction: a case report. <i>Journal of Medical Case Reports</i> , 2007, 1, 120.	0.4	2
64	A method for the visual analysis of early-stage Parkinson's disease based on virtual MRI-derived SPECT images. <i>International Journal of Imaging Systems and Technology</i> , 2012, 22, 172-176.	2.7	2
65	DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA (HD): RESULTS OF A PHASE II, PROSPECTIVE STUDY BY FONDAZIONE ITALIANA LINFOMI. <i>Hematological Oncology</i> , 2019, 37, 291-292.	0.8	2
66	The 18F phantom clinical trials qualification for 18F-FDG-PET scanning adopted by GELTAMO (Grupo Tj ETQq0 0 0 rgBT /Overlock 10 Imagen Molecular, 2021, 40, 149-154.	0.1	2
67	Dual-point FDG-PET: A novel scanning technique in Hodgkin lymphoma with bulky disease.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8077-8077.	0.8	2
68	The role of medical physicists in clinical trials across Europe. <i>Physica Medica</i> , 2022, 100, 31-38.	0.4	2
69	On-demand lung CT analysis with the M5L-CAD via the WIDEN front-end web interface and an OpenNebula-based cloud back-end. , 2012, , .		1
70	INTERIM ANALYSIS OF CENTRAL REVIEW OF END-OF-THERAPY PET IN FOLL12 TRIAL FOR FOLLICULAR LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 393-393.	0.8	1
71	Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi. <i>Annals of Hematology</i> , 2021, 100, 2547-2556.	0.8	1
72	Myocardial Metabolic Response Predicts Chemotherapy Curative Potential on Hodgkin Lymphoma: A Proof-of-Concept Study. <i>Biomedicines</i> , 2021, 9, 971.	1.4	1

#	ARTICLE	IF	CITATIONS
73	A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA. <i>Blood</i> , 2019, 134, 883-883.	0.6	1
74	Learned Deep Radiomics for Survival Analysis with Attention. <i>Lecture Notes in Computer Science</i> , 2020, , 35-45.	1.0	1
75	PET/CT Imaging of Lymphoma Outside the Western World. , 0, , 117-140.		1
76	Atorvastatin Improves Myocardial Perfusion in a Patient With Hypercholesterolemia and Single-Vessel Coronary Disease. <i>Clinical Nuclear Medicine</i> , 2006, 31, 166-167.	0.7	0
77	Breath Control Device with EKG monitoring (ABCDE) for routine imaging and therapy. , 2006, , .		0
78	Benchmark of medical dosimetry simulation using the Grid. , 2007, , .		0
79	Microdosimetry in high-resolution cellular phantoms using the very low energy electromagnetic extension of the Geant4 toolkit. , 2007, , .		0
80	Virtual MRI-derived SPECT for the visual analysis of Parkinson's disease in early stage. , 2008, , .		0
81	280. VATS (Video Assisted Thoracoscopic Surgery) with radiological guidance in hybrid operating room: Technique standardization, organizational aspects and dose optimization. <i>Physica Medica</i> , 2018, 56, 233-234.	0.4	0
82	356. ZeroDose: An automatic tool for exposure indexes retrieval from images stored in PACS system. <i>Physica Medica</i> , 2018, 56, 275-276.	0.4	0
83	[OA143] Application of new algorithms in PET image reconstruction: Preliminary results. <i>Physica Medica</i> , 2018, 52, 54-55.	0.4	0
84	326. PET scanner qualification for clinical trial: Comparison between Italian and worldwide experience. <i>Physica Medica</i> , 2018, 56, 260.	0.4	0
85	Abstract ID: 375 Quantitative imaging in nuclear medicine. <i>Physica Medica</i> , 2018, 56, 284.	0.4	0
86	281. Prostate artery embolization of benign prostate hyperplasia: Technical and dosimetric aspects. <i>Physica Medica</i> , 2018, 56, 234.	0.4	0
87	241. Radiation risk due to medical imaging in long living patients: the case of Hodgkin lymphoma. <i>Physica Medica</i> , 2018, 56, 210-211.	0.4	0
88	RADIOMICS INCREASE THE PROGNOSTIC VALUE OF CLINICAL AND PET RISK FACTORS IN DLBCL: RESULTS FROM THE PHASE 3 GOYA STUDY. <i>Hematological Oncology</i> , 2019, 37, 52-53.	0.8	0
89	PS1237 DOSE DENSE ABVD (DD \pm ABVD) AS FIRST LINE THERAPY IN EARLY \hat{e} STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTI \hat{e} CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI. <i>HemaSphere</i> , 2019, 3, 563-564.	1.2	0
90	Cualificaci3n de fantomas 18F para ensayos cl3nicos con imagen PET/TC-18F-FDG adoptada por GELTAMO (Grupo Espa3ol de Linfomas/Trasplante Aut3logo de M3dula 3sea). <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 149-154.	0.0	0

#	ARTICLE	IF	CITATIONS
91	Comparative Assessment of Different Criteria for Interim-PET Interpretation in a Cohort of Hodgkin Lymphoma Patients Treated in a Single Center.. Blood, 2009, 114, 3657-3657.	0.6	0
92	Interim-PET Scan Interpretation In the Ongoing Prospective Clinical Trial HD 0607, In Advanced-Stage Hodgkin Lymphoma: Results of the the Expert Panel Review. Blood, 2010, 116, 3891-3891.	0.6	0
93	WIDEN: A tool for medical imaging management in oncology clinical trials.. Journal of Clinical Oncology, 2012, 30, e13093-e13093.	0.8	0
94	â€ˆICD in Primary Prevention: Potential Role of Sympathetic Nerve Imagingâ€™™. The Open Cardiovascular Imaging Journal, 2013, 4, 1-3.	0.3	0
95	Role of 123I-Iobenguane Myocardial Scintigraphy in Predicting Short-term Left Ventricular Functional Recovery: An Interesting Image. Journal of Clinical Imaging Science, 2015, 5, 56.	0.4	0
96	PET-Derived Metabolic Volume Metrics in the Hodgkin Lymphoma. , 2016, , 65-98.		0
97	Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial. Blood, 2016, 128, 992-992.	0.6	0
98	A core laboratory approach to large-scale radiomics and machine-learning prediction of DLBCL outcomes after first-line treatment using results from the phase III GOYA study.. Journal of Clinical Oncology, 2019, 37, e19042-e19042.	0.8	0